The amyloid-beta (A beta) aggregation pathway is a key target in efforts to discover therapeutics that prevent or delay the onset of Alzheimer's disease. Efforts at rational drug design, however, are hampered by uncertainties about the precise nature of the toxic aggregate. In contrast, high-throughput screening of compound libraries does not require a detailed understanding of the structure of the toxic species, and can provide an unbiased method for the discovery of small molecules that may lead to effective therapeutics. Here, we show that small molecule microarrays (SMMs) represent a particularly promising tool for identifying compounds that bind the A beta peptide. Microarray slides with thousands of compounds immobilized on their surface were screened for binding to fluorescently labeled A beta. Seventy-nine compounds were identified by the SMM screen, and then assayed for their ability to inhibit the A beta-induced killing of PC12 cells. Further experiments focused on exploring the mechanism of rescue for one of these compounds: Electron microscopy and Congo red binding showed that the compound enhances fibril formation, and suggest that it may rescue cells by accelerating A beta aggregation past an early toxic oligomer. These findings demonstrate that the SMM screen for binding to A beta is effective at identifying compounds that reduce A beta toxicity, and can reveal potential therapeutic leads without the biases inherent in methods that focus on inhibitors of aggregation.